The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. Our stock price is volatile and may be affected by a number of events.

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

JANUARY 3, 2021

(Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available. About PBGM01. About Passage Bio.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

. – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options. FTD is a debilitating form of early onset dementia that currently has no approved disease-modifying therapies. “We

Therapies 52

Therapies Treatment Clinical Trials FDA 52

The Pharma Data

OCTOBER 21, 2020

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8% There was a 1.08 combined dose groups; 6.5% placebo; p=0.024). REGN-COV2 was well tolerated in the trial.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 17, 2020

In the initial 275 patients, rates of adverse events (AEs) were similar among groups. If the therapy proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. , who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JANUARY 31, 2021

No serious adverse events related to the vaccine candidates studied were reported. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The candidate vaccines were given in two doses, three weeks apart. About Dynavax.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 31, 2021

(Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

NOVEMBER 22, 2020

There were no serious adverse safety events. They use mRNA that codes for the spike protein in the SARS-CoV-2 virus, which is embedded in a nanolipid particle—basically a minuscule fat molecule. When injected into the body, cells churn out the spike protein, which causes the body’s immune system to recognize the virus.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

OCTOBER 6, 2021

A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , AR-711 (COVID-19).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 31, 2021

” Dr. Richard Hatchett , Chief Executive Officer of CEPI, commented: “To end the acute phase of this pandemic, and to control the virus in the longer term, the world needs multiple safe and effective vaccines which can be deployed in a range of populations and countries. About CpG 1018.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

DECEMBER 28, 2020

Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 23, 2020

No serious safety events related to the vaccine have been confirmed. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. AZD1222 was well tolerated across both dosing regimens. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

DECEMBER 30, 2020

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The overall reported rates of serious adverse events were 0.7% in the vaccine group and 0.8%

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

SEPTEMBER 7, 2020

If your anxiety persists, there are lots of self-help books on the best therapies, such as cognitive behavioural therapy (CBT), which is also provided on the NHS. CBT is a talking therapy which helps people deal with overwhelming problems by breaking them down into smaller chunks. Who is most at risk?

Virus 52

Virus Therapies Treatment Science 52

The Pharma Data

MARCH 1, 2022

We look forward to discussing this further with FDA over the coming months so that we can make this investigational new therapy available to people living with multidrug-resistant HIV as soon as possible,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

FDA 52

FDA Treatment Science Therapies 52

The Pharma Data

SEPTEMBER 12, 2020

The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

AUGUST 21, 2020

As the pharma community continue to research and develop hundreds of potential therapies to combat the Covid-19 pandemic, very few initiatives are yet to cross the finishing line into the commercial market. REGN -COV2 could be a critical line of defense against the Covid-19 pandemic.”.

Vaccine 52

Vaccine Pharmacy Clinical Trials Virus 52

The Pharma Data

JANUARY 24, 2021

These statements reflect management’s beliefs with respect to future events and are based on information currently available to management. This marks the third US clinical site that has obtained both study level and site IRB approval through a central IRB. Additional information is available at www.theralase.com and www.sedar.com.

Pharmaceutical Companies 52

Pharmaceutical Companies Virus Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 31, 2021

Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, in the proprietary dual PRRT therapy.

Small Molecule 40

Small Molecule FDA Approval Trials Therapies 40

The Pharma Data

MAY 7, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer- BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

AUGUST 20, 2020

We are proud to share our findings with the scientific community as we continue our work to deliver a safe and effective vaccine to combat this devastating virus,” said Kathrin U. Systemic events after administration of BNT162b2 were milder than those with BNT162b1. No severe systemic events were reported by older BNT162b2 recipients.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

JANUARY 27, 2021

TD-0148A is a potential novel new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment resistant severe depression and post-traumatic stress disorder. For further information please visit www.abetterlifepharma.com.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52

The Pharma Data

JULY 21, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 18, 2021

Napoleone Ferrara, a member of OKYO’s Scientific Advisory Board, will be spearheading this effort at OKYO to advance chemerin and its associated analogues for the treatment of patients with SARS-CoV-2 virus and ARDS. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders.

Science 40

Science Virus Treatment Disease 40

The Pharma Data

SEPTEMBER 5, 2021

The most frequently reported adverse events with tezepelumab were nasopharyngitis, upper respiratory tract infection and headache. Food and Drug Administration Breakthrough Therapy Designation was granted to tezepelumab in September 2018 for patients with severe asthma, without an eosinophilic phenotype. Outside the U.S.,

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

OCTOBER 15, 2020

Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

The Pharma Data

SEPTEMBER 9, 2020

BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About the Phase 2/3 Study. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

MAY 6, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

New Drug Approvals

JANUARY 31, 2024

BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

The Pharma Data

JUNE 24, 2021

This is a meaningful moment for adolescents, parents and entire families who are seeking protection from this virus and a return to normalcy,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at [link]. The Pfizer?BioNTech

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

Elrig

FEBRUARY 23, 2023

That’s why we created the Research & Innovation (R&I) Conference over 5 years ago, now one of ELRIG’s renowned flagship events. It brings together leading scientists, researchers, and entrepreneurs with bold ideas, and one shared ambition: to develop the next generation of therapies to cure more patients around the world.

Research 40

Research Disease Science Drugs 40